Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a N/A change, with the full-year FY2025 number at $11.4 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $11.4 million for Q4 2025 at Kymera Therapeutics, down from $14.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $64.7 million in Q1 2021 to a low of $3.2 million in Q2 2024.
  • A 5-year average of $27.6 million and a median of $23.9 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 4.36% in 2024; the steepest drop was 84.38% in 2024.
  • Kymera Therapeutics' Non-Current Deffered Revenue stood at $39.3 million in 2021, then fell by 28.74% to $28.0 million in 2022, then crashed by 40.11% to $16.8 million in 2023, then tumbled by 80.98% to $3.2 million in 2024, then skyrocketed by 258.73% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Non-Current Deffered Revenue are $11.4 million (Q4 2025), $14.0 million (Q3 2025), and $3.2 million (Q2 2024).